No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Epacadostat is a type of oncology drug that works by inhibiting the enzyme indoleamine 2,3-dioxygenase 1 (IDO1). This enzyme is involved in the regulation of the immune system and is often overactive in cancer cells. By blocking IDO1, epacadostat can help the body's immune system to recognize and attack cancer cells. Epacadostat is currently being studied in combination with other cancer treatments, such as chemotherapy and immunotherapy, to improve outcomes for patients with advanced cancers.
Epacadostat is a relatively new drug, and the market is still in its early stages. However, there are a number of companies that are researching and developing epacadostat-based treatments. These include Merck, Incyte, Bristol-Myers Squibb, and Novartis. Additionally, several biotechnology companies are also researching and developing epacadostat-based treatments, such as Agenus, Immunocore, and NewLink Genetics. Show Less Read more
